EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Adrian Hunt iD, Yohei Hashimoto, Stephanie Young, Jennifer Arnold, Justin Game, Claire Hooper, Andrew Field, Richard Barry, Daniel Barthelmes, Mark Gillies

Clinical & Experimental Ophthalmology · 2025-12 · 53 (9) · 1156-1167

DOI: 10.1111/ceo.14589 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 27.07.2025. Verfasst von Adrian Hunt und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Registries, Wet Macular Degeneration, Drug Substitution. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Royal Australian and New Zealand College of Ophthalmologists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care.

Methods

Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness! registry switched to faricimab from aflibercept 2 mg, ranibizumab, or bevacizumab between 1st January—1st August 2023 in Australia.

Results

One‐year completion rates were high (335/383 [88%]). The proportion of choroidal neovascular (CNV) lesions graded as inactive increased from 39% at switch to 63% at 12 months ( p < 0.01). Mean visual acuity (95% Confidence Interval) decreased from 70.0 (68.6, 71.5) to 68.4 (66.7, 70.1) logarithm of the minimum angle of resolution letters (both approx. 6/12). Mean treatment intervals increased from 7.2 to 10.5 weeks ( p < 0.01). Eyes with active CNV at switch maintained mean VA −0.5 (−1.7, +0.7) letters; 50% were inactivated at 12 months. Eyes with inactive CNV at switch lost −3.5 (−5.0, −1.9) letters; 15% had reactivation at 12 months. Switchback occurred in 64/383 eyes (17%), predominantly to aflibercept 2 mg, that lost −1.9 letters without interval change at 12 months. Adverse outcomes were in keeping with previous reports, with no cases of occlusive retinal vasculitis.

Conclusions

We found that faricimab inactivated a significant proportion of CNV lesions that had been active using 1st generation VEGF inhibitors, with a significant extension of the treatment interval. A small reduction in VA occurred in switchers and eyes not switched through the same period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesWet Macular DegenerationDrug SubstitutionHumansAngiogenesis InhibitorsMaleFemaleVisual AcuityIntravitreal InjectionsAgedRanibizumabVascular Endothelial Growth Factor ARecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAged, 80 and overTreatment OutcomeTomography, Optical CoherenceBevacizumabFluorescein AngiographyFollow-Up StudiesAntibodies, Bispecific

Stichwörter der Autor:innen

AMDFaricimabmaculaneovascularswitching

Substanzen

Angiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AafliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorBevacizumabVEGFA protein, humanfaricimabAntibodies, Bispecific

Autor:innen und Institutionen

  • The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia.
  • Gladesville Eye Specialists, Gladesville, New South Wales, Australia.
  • Marsden Eye Specialists, Parramatta, New South Wales, Australia.
  • Port Macquarie Eye Centre, Port Macquarie, New South Wales, Australia.
  • Visionary Eye Specialists, Hurstville, New South Wales, Australia.

ORCID-Profile: Adrian Hunt

Förderung

  • National Health and Medical Research Council
  • Royal Australian and New Zealand College of Ophthalmologists

Zitieren

APA

Hunt, A., Hashimoto, Y., Young, S., Arnold, J., Game, J., Hooper, C., Field, A., Barry, R., Barthelmes, D., & Gillies, M. (2025). Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry. Clinical & Experimental Ophthalmology, 53(9), 1156-1167. https://doi.org/10.1111/ceo.14589

Vancouver

Hunt A, Hashimoto Y, Young S, Arnold J, Game J, Hooper C, et al. Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry. Clinical & Experimental Ophthalmology. 2025;53(9):1156-1167. doi:10.1111/ceo.14589

BibTeX
@article{Hunt2025,
  author = {Hunt, Adrian and Hashimoto, Yohei and Young, Stephanie and Arnold, Jennifer and Game, Justin and Hooper, Claire and Field, Andrew and Barry, Richard and Barthelmes, Daniel and Gillies, Mark},
  title = {Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2025},
  volume = {53},
  number = {9},
  pages = {1156--1167},
  doi = {10.1111/ceo.14589}
}
Kostenlos starten →